Back to Journals » International Journal of Nanomedicine » Volume 13

Hypoxia-activated prodrugs and redox-responsive nanocarriers

Authors Zeng Y, Ma J, Zhan Y, Xu X, Zeng Q, Liang J, Chen X

Received 1 June 2018

Accepted for publication 22 August 2018

Published 18 October 2018 Volume 2018:13 Pages 6551—6574

DOI https://doi.org/10.2147/IJN.S173431

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Colin Mak

Peer reviewer comments 2

Editor who approved publication: Dr Lei Yang


Yun Zeng,1,* Jingwen Ma,2,* Yonghua Zhan,1 Xinyi Xu,1 Qi Zeng,1 Jimin Liang,1 Xueli Chen1

1Engineering Research Center of Molecular and Neuro Imaging of the Ministry of Education, School of Life Science and Technology, Xidian University, Xi’an 710071, Shaanxi Province, People’s Republic of China; 2Department of Pharmaceutical Analysis, China Pharmaceutical University, Nanjing 210009, Jiangsu Province, People’s Republic of China

*These authors contributed equally to this work

Abstract: Hypoxia is one of the marked features of malignant tumors, which is associated with several adaptation changes in the microenvironment of tumor cells. Therefore, targeting tumor hypoxia is a research hotspot for cancer therapy. In this review, we summarize the developing chemotherapeutic drugs for targeting hypoxia, including quinones, nitroaromatic/nitroimidazole, N-oxides, and transition metal complexes. In addition, redox-responsive bonds, such as nitroimidazole groups, azo-groups, and disulfide bonds, are frequently used in drug delivery systems for targeting the redox environment of tumors. Both hypoxia-activated prodrugs and redox-responsive drug delivery nanocarriers have significant effects on targeting tumor hypoxia for cancer therapy. Hypoxia-activated prodrugs are commonly used in clinical trials with favorable prospects, while redox-responsive nanocarriers are currently at the experimental stage.

Keywords: antitumor drugs, hypoxia, nanoparticles, redox-sensitive, tumor therapy
 

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]